Cited 8 times in
Clinical outcomes of everolimus in patients with advanced, nonfunctioning pancreatic neuroendocrine tumors: a multicenter study in Korea
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 방승민 | - |
dc.contributor.author | 송시영 | - |
dc.date.accessioned | 2018-07-20T08:09:10Z | - |
dc.date.available | 2018-07-20T08:09:10Z | - |
dc.date.issued | 2017 | - |
dc.identifier.issn | 0344-5704 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/160894 | - |
dc.description.abstract | PURPOSE: Everolimus is a standard treatment option for advanced pancreatic neuroendocrine tumors (pNETs). This multicenter study evaluated the efficacy and safety of everolimus in low and intermediate grade advanced pNETs. METHODS: Tumors were graded according to the World Health Organization 2010 classification system. Patients with low or intermediate grade pNETs who received everolimus as first- or second-line chemotherapy between 2002 and 2014 were included. RESULTS: A total of 40 patients with metastatic or recurrent pNETs were included in this study. The median age was 54.5 years (range 19-83 years). Twelve patients (30%) experienced recurrence. There were 11 patients (27.5%) with low grade pNETs and 29 (72.5%) with intermediate. Everolimus was administered as first-line therapy in 30 patients (75%) and as second-line therapy in 10 patients (25%). The median progression-free survival (PFS) of patients with low and intermediate grade pNETs was significantly different (median not reached vs. 11 months, P = 0.015). On multivariate analysis, tumor grade (intermediate grade; HR 6.52, 95% CI 1.31-32.27, P = 0.022) was the only independent prognostic factor for PFS in pNETs. The most common adverse events were stomatitis, skin rash, and anemia. CONCLUSIONS: World Health Organization 2010 grade is the most important determinant for PFS in patients undergoing everolimus treatment for pNETs with an acceptable incidence of adverse events. | - |
dc.description.statementOfResponsibility | restriction | - |
dc.language | English | - |
dc.publisher | Springer Verlag | - |
dc.relation.isPartOf | CANCER CHEMOTHERAPY AND PHARMACOLOGY | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.subject.MESH | Adult | - |
dc.subject.MESH | Aged | - |
dc.subject.MESH | Aged, 80 and over | - |
dc.subject.MESH | Anemia/chemically induced | - |
dc.subject.MESH | Anemia/epidemiology | - |
dc.subject.MESH | Antineoplastic Agents/adverse effects | - |
dc.subject.MESH | Antineoplastic Agents/therapeutic use* | - |
dc.subject.MESH | Disease-Free Survival | - |
dc.subject.MESH | Everolimus/adverse effects | - |
dc.subject.MESH | Everolimus/therapeutic use* | - |
dc.subject.MESH | Exanthema/chemically induced | - |
dc.subject.MESH | Exanthema/epidemiology | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Middle Aged | - |
dc.subject.MESH | Neoplasm Grading | - |
dc.subject.MESH | Neoplasm Recurrence, Local | - |
dc.subject.MESH | Pancreatic Neoplasms/drug therapy* | - |
dc.subject.MESH | Pancreatic Neoplasms/pathology | - |
dc.subject.MESH | Prognosis | - |
dc.subject.MESH | Republic of Korea | - |
dc.subject.MESH | Retrospective Studies | - |
dc.subject.MESH | Stomatitis/chemically induced | - |
dc.subject.MESH | Stomatitis/epidemiology | - |
dc.subject.MESH | Treatment Outcome | - |
dc.subject.MESH | Young Adult | - |
dc.title | Clinical outcomes of everolimus in patients with advanced, nonfunctioning pancreatic neuroendocrine tumors: a multicenter study in Korea | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine | - |
dc.contributor.department | Dept. of Internal Medicine | - |
dc.contributor.googleauthor | Kyong Joo Lee | - |
dc.contributor.googleauthor | Jae Hee Cho | - |
dc.contributor.googleauthor | Sang Hyub Lee | - |
dc.contributor.googleauthor | Si Young Song | - |
dc.contributor.googleauthor | Kwang Hyuk Lee | - |
dc.contributor.googleauthor | Seok Jeong | - |
dc.contributor.googleauthor | Ji Kon Ryu | - |
dc.contributor.googleauthor | Sang Myung Woo | - |
dc.contributor.googleauthor | Seungmin Bang | - |
dc.contributor.googleauthor | Jong Kyun Lee | - |
dc.contributor.googleauthor | Tae Hoon Lee | - |
dc.contributor.googleauthor | Woo Hyun Paik | - |
dc.contributor.googleauthor | Yong Tae Kim | - |
dc.contributor.googleauthor | Woo Jin Lee | - |
dc.identifier.doi | 10.1007/s00280-017-3421-7 | - |
dc.contributor.localId | A01786 | - |
dc.contributor.localId | A02035 | - |
dc.relation.journalcode | J00437 | - |
dc.identifier.eissn | 1432-0843 | - |
dc.identifier.pmid | 28884280 | - |
dc.identifier.url | https://link.springer.com/article/10.1007%2Fs00280-017-3421-7 | - |
dc.subject.keyword | Everolimus | - |
dc.subject.keyword | Pancreatic neuroendocrine tumor | - |
dc.subject.keyword | Prognosis | - |
dc.subject.keyword | Tumor grade | - |
dc.subject.keyword | World Health Organization classification | - |
dc.contributor.alternativeName | Bang, Seung Min | - |
dc.contributor.alternativeName | Song, Si Young | - |
dc.contributor.affiliatedAuthor | Bang, Seung Min | - |
dc.contributor.affiliatedAuthor | Song, Si Young | - |
dc.citation.volume | 80 | - |
dc.citation.number | 4 | - |
dc.citation.startPage | 799 | - |
dc.citation.endPage | 805 | - |
dc.identifier.bibliographicCitation | CANCER CHEMOTHERAPY AND PHARMACOLOGY, Vol.80(4) : 799-805, 2017 | - |
dc.identifier.rimsid | 60773 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.